A 1:1 combination blend pairing Cagrilintide (long-acting amylin/calcitonin receptor agonist) with Semaglutide (GLP-1 receptor agonist) at 5mg each per vial (10mg total), for researchers studying the interaction between amylin and GLP-1 receptor pathways in in-vitro and in-vivo models. For laboratory research use only. Not for human consumption.